CA3000824C - Extreme reverse transcription pcr - Google Patents
Extreme reverse transcription pcr Download PDFInfo
- Publication number
- CA3000824C CA3000824C CA3000824A CA3000824A CA3000824C CA 3000824 C CA3000824 C CA 3000824C CA 3000824 A CA3000824 A CA 3000824A CA 3000824 A CA3000824 A CA 3000824A CA 3000824 C CA3000824 C CA 3000824C
- Authority
- CA
- Canada
- Prior art keywords
- pcr
- concentration
- polymerase
- time
- primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000003757 reverse transcription PCR Methods 0.000 title claims abstract description 87
- 238000000034 method Methods 0.000 claims abstract description 79
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 238000003752 polymerase chain reaction Methods 0.000 claims description 359
- 238000010839 reverse transcription Methods 0.000 claims description 197
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 125
- 230000003321 amplification Effects 0.000 claims description 124
- 102000004190 Enzymes Human genes 0.000 claims description 79
- 108090000790 Enzymes Proteins 0.000 claims description 79
- 238000004925 denaturation Methods 0.000 claims description 73
- 230000036425 denaturation Effects 0.000 claims description 73
- 241000713869 Moloney murine leukemia virus Species 0.000 claims description 63
- 230000001351 cycling effect Effects 0.000 claims description 61
- 108091023037 Aptamer Proteins 0.000 claims description 40
- 230000002441 reversible effect Effects 0.000 claims description 33
- 102100034343 Integrase Human genes 0.000 claims description 30
- 239000011541 reaction mixture Substances 0.000 claims description 28
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 27
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 27
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 26
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 25
- 150000007523 nucleic acids Chemical class 0.000 claims description 25
- 230000002829 reductive effect Effects 0.000 claims description 25
- 102000039446 nucleic acids Human genes 0.000 claims description 23
- 108020004707 nucleic acids Proteins 0.000 claims description 23
- 239000012472 biological sample Substances 0.000 claims description 17
- 108091008102 DNA aptamers Proteins 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 14
- 108091008103 RNA aptamers Proteins 0.000 claims description 11
- 235000000346 sugar Nutrition 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 239000003638 chemical reducing agent Substances 0.000 claims description 5
- 239000003607 modifier Substances 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 125000000647 trehalose group Chemical group 0.000 claims 1
- 238000011534 incubation Methods 0.000 abstract description 33
- 239000000047 product Substances 0.000 description 142
- 238000006243 chemical reaction Methods 0.000 description 122
- 238000000137 annealing Methods 0.000 description 109
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 76
- 239000000523 sample Substances 0.000 description 76
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 69
- 108020004414 DNA Proteins 0.000 description 66
- 230000000694 effects Effects 0.000 description 60
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 56
- 238000002844 melting Methods 0.000 description 49
- 230000008018 melting Effects 0.000 description 49
- 239000000243 solution Substances 0.000 description 40
- 229910001629 magnesium chloride Inorganic materials 0.000 description 38
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 33
- 241000725643 Respiratory syncytial virus Species 0.000 description 32
- 239000000872 buffer Substances 0.000 description 32
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 31
- 239000000499 gel Substances 0.000 description 30
- 238000010438 heat treatment Methods 0.000 description 28
- 238000003753 real-time PCR Methods 0.000 description 24
- 239000000975 dye Substances 0.000 description 23
- 239000012634 fragment Substances 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 21
- 108091093088 Amplicon Proteins 0.000 description 20
- 238000012544 monitoring process Methods 0.000 description 20
- 230000007423 decrease Effects 0.000 description 18
- 238000001816 cooling Methods 0.000 description 17
- 230000003247 decreasing effect Effects 0.000 description 17
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 16
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 16
- 239000007983 Tris buffer Substances 0.000 description 16
- 239000000539 dimer Substances 0.000 description 16
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 16
- 239000002299 complementary DNA Substances 0.000 description 15
- 239000013642 negative control Substances 0.000 description 15
- 238000011002 quantification Methods 0.000 description 15
- 238000012546 transfer Methods 0.000 description 13
- 230000000670 limiting effect Effects 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 230000033001 locomotion Effects 0.000 description 11
- 230000035484 reaction time Effects 0.000 description 11
- 239000011521 glass Substances 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 239000000835 fiber Substances 0.000 description 9
- 102000053602 DNA Human genes 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 8
- 108010006785 Taq Polymerase Proteins 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000011777 magnesium Substances 0.000 description 8
- 230000004544 DNA amplification Effects 0.000 description 7
- 239000004033 plastic Substances 0.000 description 7
- 229920003023 plastic Polymers 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- 102100033822 A-kinase anchor protein 10, mitochondrial Human genes 0.000 description 6
- 101000779365 Homo sapiens A-kinase anchor protein 10, mitochondrial Proteins 0.000 description 6
- 101000974726 Homo sapiens Potassium voltage-gated channel subfamily E member 1 Proteins 0.000 description 6
- 101710203526 Integrase Proteins 0.000 description 6
- 102100022755 Potassium voltage-gated channel subfamily E member 1 Human genes 0.000 description 6
- 239000011543 agarose gel Substances 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 238000004064 recycling Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000005382 thermal cycling Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000701959 Escherichia virus Lambda Species 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000010432 diamond Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 101000616974 Homo sapiens Pumilio homolog 1 Proteins 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 102100021672 Pumilio homolog 1 Human genes 0.000 description 3
- 208000020329 Zika virus infectious disease Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- -1 dNTPs Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000011554 ferrofluid Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000011880 melting curve analysis Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 241000589500 Thermus aquaticus Species 0.000 description 2
- 241000907316 Zika virus Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 229910052733 gallium Inorganic materials 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000036632 reaction speed Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- NEWKHUASLBMWRE-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine Chemical compound CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 NEWKHUASLBMWRE-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N Acetylene Chemical compound C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000003844 DNA helicases Human genes 0.000 description 1
- 108090000133 DNA helicases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229920004943 Delrin® Polymers 0.000 description 1
- 241000239047 Emberizoides herbicola Species 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 229910019077 Mg—F Inorganic materials 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 206010051141 Myeloblastoma Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 238000004616 Pyrometry Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241001137860 Rotavirus A Species 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 101710097146 Uncharacterized protein HKLF1 Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000012443 analytical study Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000007846 asymmetric PCR Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229920006015 heat resistant resin Polymers 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 238000013345 light-cycler PCR Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- SQMWSBKSHWARHU-SDBHATRESA-N n6-cyclopentyladenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 SQMWSBKSHWARHU-SDBHATRESA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000012803 optimization experiment Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical compound NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 102200133007 rs1805128 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000012409 standard PCR amplification Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L7/00—Heating or cooling apparatus; Heat insulating devices
- B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
- B01L7/525—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples with physical movement of samples between temperature zones
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L7/00—Heating or cooling apparatus; Heat insulating devices
- B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
- B01L7/525—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples with physical movement of samples between temperature zones
- B01L7/5255—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples with physical movement of samples between temperature zones by moving sample containers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/18—Means for temperature control
- B01L2300/1838—Means for temperature control using fluid heat transfer medium
- B01L2300/185—Means for temperature control using fluid heat transfer medium using a liquid as fluid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Clinical Laboratory Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562251400P | 2015-11-05 | 2015-11-05 | |
| US62/251,400 | 2015-11-05 | ||
| PCT/US2016/060650 WO2017079636A1 (en) | 2015-11-05 | 2016-11-04 | Extreme reverse transcription pcr |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3000824A1 CA3000824A1 (en) | 2017-05-11 |
| CA3000824C true CA3000824C (en) | 2024-02-13 |
Family
ID=58663164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3000824A Active CA3000824C (en) | 2015-11-05 | 2016-11-04 | Extreme reverse transcription pcr |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10900074B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3337615B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7319646B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108367287B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3000824C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3337615T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2916153T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3337615T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017079636A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018023360A (ja) * | 2016-07-29 | 2018-02-15 | セイコーエプソン株式会社 | 核酸増幅反応方法、試薬、および試薬の使用方法 |
| EP3615693A4 (en) * | 2017-04-28 | 2021-01-13 | Spartan Bioscience Inc. | DIRECT ANALYSIS OF NUCLEIC ACIDS OF ENVIRONMENTAL AND BIOLOGICAL SAMPLES |
| GB201812192D0 (en) | 2018-07-26 | 2018-09-12 | Ttp Plc | Variable temperature reactor, heater and control circuit for the same |
| CA3126398A1 (en) * | 2019-01-17 | 2020-07-23 | Northwestern University | Rapid reverse transcription quantitative polymerase chain reaction |
| WO2020175406A1 (ja) * | 2019-02-28 | 2020-09-03 | 池田食研株式会社 | 遺伝子増幅法及び遺伝子増幅用キット |
| SG10201905641YA (en) * | 2019-06-19 | 2021-01-28 | Delta Electronics Int’L Singapore Pte Ltd | Primer pair, kit and method for detecting zika virus |
| US11254979B2 (en) | 2020-06-01 | 2022-02-22 | Shaheen Innovations Holding Limited | Systems and devices for infectious disease screening |
| US11730193B2 (en) | 2019-12-15 | 2023-08-22 | Shaheen Innovations Holding Limited | Hookah device |
| JP7580877B2 (ja) * | 2020-03-30 | 2024-11-12 | 国立研究開発法人産業技術総合研究所 | 核酸増幅用組成物 |
| JP2023527573A (ja) | 2020-06-01 | 2023-06-29 | シャヒーン イノベーションズ ホールディング リミテッド | 感染症検査システム |
| AU2021285406B2 (en) | 2020-06-01 | 2024-11-28 | Shaheen Innovations Holding Limited | An infectious disease screening device |
| GB202115637D0 (en) * | 2021-11-01 | 2021-12-15 | Anglia Ruskin Univ Higher Education Corporation | Nucleic acid amplification method |
| CN118302539A (zh) | 2021-12-21 | 2024-07-05 | 凯杰有限公司 | 扩增样品中的rna的方法 |
| CN114885450B (zh) * | 2022-07-11 | 2022-09-20 | 中国飞机强度研究所 | 一种空天飞机测试用的极高温极低温热强度循环试验系统 |
| WO2025049638A1 (en) * | 2023-08-29 | 2025-03-06 | Access Medical Systems, Ltd. | Devices for rapid amplifying nucleic acid and method of using the same |
| CN117363620B (zh) * | 2023-12-08 | 2024-03-01 | 北京全式金生物技术股份有限公司 | 一种特异性结合反转录酶的rna适配体及其应用 |
| CN119876354A (zh) * | 2025-01-24 | 2025-04-25 | 申联生物医药（上海）股份有限公司 | 一种全预混式荧光pcr试剂盒及稳定剂 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2065719A1 (en) | 1991-04-30 | 1992-10-31 | John B. Findlay | Nucleic acid amplification and detection methods using rapid polymerase chain reaction cycle |
| US5436149A (en) | 1993-02-19 | 1995-07-25 | Barnes; Wayne M. | Thermostable DNA polymerase with enhanced thermostability and enhanced length and efficiency of primer extension |
| AU7551594A (en) | 1993-07-29 | 1995-02-28 | MURASHIGE, Kate H. | Method for recognition of the nucleotide sequence of a purified dna segment |
| EP0833944B1 (en) | 1995-06-07 | 2009-01-07 | Gilead Sciences, Inc. | Nucleic acid ligands that bind to and inhibit dna polymerases |
| AU7073096A (en) * | 1995-09-19 | 1997-04-09 | University Of Massachusetts | Inhibited biological degradation of oligodeoxynucleotides |
| US6210882B1 (en) | 1998-01-29 | 2001-04-03 | Mayo Foundation For Medical Education And Reseach | Rapid thermocycling for sample analysis |
| US6300073B1 (en) * | 1999-10-01 | 2001-10-09 | Clontech Laboratories, Inc. | One step RT-PCR methods, enzyme mixes and kits for use in practicing the same |
| KR20030073875A (ko) | 2002-03-13 | 2003-09-19 | 주식회사 하이닉스반도체 | 반도체소자의 소자분리패턴 형성방법 |
| US8232091B2 (en) | 2006-05-17 | 2012-07-31 | California Institute Of Technology | Thermal cycling system |
| JP5191041B2 (ja) * | 2007-04-05 | 2013-04-24 | エフ．ホフマン−ラ ロシュ アーゲー | 急速ワンステップｒｔ−ｐｃｒ |
| DE102008008313A1 (de) * | 2008-02-07 | 2009-08-13 | Qiagen Gmbh | Amplifikation von bisulfitierten Nukleinsäuren |
| WO2009105499A1 (en) | 2008-02-20 | 2009-08-27 | Termaat Joel R | Thermocycler and sample vessel for rapid amplification of dna |
| CA2658520C (en) | 2008-03-19 | 2016-11-08 | F. Hoffmann-La Roche Ag | Nucleic acid amplification in the presence of modified randomers |
| DK2644707T3 (en) * | 2008-04-30 | 2015-06-29 | Integrated Dna Tech Inc | RNase-H-based assays using modified RNA monomers. |
| WO2010059323A2 (en) | 2008-11-18 | 2010-05-27 | Life Technologies Corporation | Sequence amplification with target primers |
| CN101407850B (zh) | 2008-11-20 | 2011-01-05 | 江苏出入境检验检疫局动植物与食品检测中心 | 猴痘病毒的pcr快速检测试剂盒及检测方法 |
| ES2544288T3 (es) | 2010-02-26 | 2015-08-28 | Life Technologies Corporation | Fast PCR para la genotipificación de STR |
| CN101935697B (zh) * | 2010-04-16 | 2015-11-25 | 中生方政生物技术有限公司 | 用于核酸序列检测的方法和试剂盒 |
| ES2908415T3 (es) | 2010-06-21 | 2022-04-29 | Life Technologies Corp | Composición y método para la síntesis y amplificación de ácidos nucleicos mediante el uso de RT |
| US9168530B2 (en) | 2010-12-17 | 2015-10-27 | Bjs Ip Ltd. | Methods and systems for fast PCR heating |
| ES2889348T3 (es) * | 2012-05-24 | 2022-01-12 | Univ Utah Res Found | Dispositivo para PCR extrema |
| US9353409B2 (en) * | 2013-01-15 | 2016-05-31 | Jun Euihum Lee | Compositions and methods for RT-PCR |
| US11028432B2 (en) | 2013-11-05 | 2021-06-08 | Biofire Diagnostics, Llc | Induction PCR |
-
2016
- 2016-11-04 WO PCT/US2016/060650 patent/WO2017079636A1/en not_active Ceased
- 2016-11-04 CA CA3000824A patent/CA3000824C/en active Active
- 2016-11-04 DK DK16863087.9T patent/DK3337615T3/da active
- 2016-11-04 EP EP16863087.9A patent/EP3337615B1/en active Active
- 2016-11-04 ES ES16863087T patent/ES2916153T3/es active Active
- 2016-11-04 US US15/771,968 patent/US10900074B2/en active Active
- 2016-11-04 JP JP2018543065A patent/JP7319646B2/ja active Active
- 2016-11-04 PL PL16863087.9T patent/PL3337615T3/pl unknown
- 2016-11-04 CN CN201680064778.6A patent/CN108367287B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018538007A (ja) | 2018-12-27 |
| EP3337615A1 (en) | 2018-06-27 |
| CA3000824A1 (en) | 2017-05-11 |
| DK3337615T3 (da) | 2022-05-09 |
| CN108367287A (zh) | 2018-08-03 |
| CN108367287B (zh) | 2021-04-02 |
| WO2017079636A1 (en) | 2017-05-11 |
| PL3337615T3 (pl) | 2022-08-29 |
| US10900074B2 (en) | 2021-01-26 |
| EP3337615B1 (en) | 2022-02-16 |
| EP3337615A4 (en) | 2019-03-06 |
| ES2916153T3 (es) | 2022-06-28 |
| JP7319646B2 (ja) | 2023-08-02 |
| US20190002954A1 (en) | 2019-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3000824C (en) | Extreme reverse transcription pcr | |
| US11834708B2 (en) | Methods for fast nucleic acid amplification | |
| EP3066222B1 (en) | Induction pcr | |
| EP3562592B1 (en) | Fast pcr with molecular crowding |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211023 |
|
| EEER | Examination request |
Effective date: 20211023 |
|
| EEER | Examination request |
Effective date: 20211023 |
|
| EEER | Examination request |
Effective date: 20211023 |
|
| EEER | Examination request |
Effective date: 20211023 |
|
| EEER | Examination request |
Effective date: 20211023 |
|
| EEER | Examination request |
Effective date: 20211023 |
|
| EEER | Examination request |
Effective date: 20211023 |
|
| EEER | Examination request |
Effective date: 20211023 |
|
| EEER | Examination request |
Effective date: 20211023 |
|
| EEER | Examination request |
Effective date: 20211023 |